The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide - Concepedia

Concepedia

Publication | Open Access

The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide

DOI Full Paper Access

46

Citations

16

References

2006

Year

Owen A. O’Connor, Emily A. Smith, Lorraine E. Toner, Julie Teruya‐Feldstein, Stanley Frankel, Mark Rolfe, Xiaohui Wei, Shujun Liu, Guido Marcucci, Kenneth K. Chan,

Clinical Cancer Research

Abstract

The use of Bcl-2-directed therapy and a proteasome inhibitor sensitizes human lymphoma cells to cytotoxic drugs like cyclophosphamide. This combination may offer new opportunities for integrating novel targeted therapies with conventional chemotherapy.

References

	Year	Citations

Page 1